Biohaven Ltd. (BHVN)
NYSE
Healthcare
Biotechnology
$14.58
▲ +0.62%
Market Cap
$2.20B
Sector
Healthcare
Industry
Biotechnology
Beta
3.16
52-Wk Range
7.48-18.566
CEO
Vladimir Coric
Country
US
Currency
USD
Biohaven Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in New Haven, CT, US. The stock last traded at $14.58, up 0.62% on the session, giving a market capitalisation of $2.20B. On trailing twelve-month figures it carries a trailing P/E of -3.14, a net margin of 0.0%. Its beta of 3.16 implies it has historically moved more than the broad market.
Valuation & profitability (TTM)
P/E
-3.14
Price / Sales
0.00
Price / Book
179.70
EV / EBITDA
-3.91
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
23.92
Current ratio
4.73
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
274
IPO date
2022-09-23
Headquarters
New Haven, CT, US
About Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Comparable companies
Biohaven Ltd. is most often compared with the following Healthcare names:
More research on BHVN
Open full interactive analysis & DCF →